Published in Neuropsychopharmacology on February 10, 2010
Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology (2010) 2.74
Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron (2012) 1.81
Prolonged disynaptic inhibition in the cortex mediated by slow, non-α7 nicotinic excitation of a specific subset of cortical interneurons. J Neurosci (2012) 1.49
Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci (2011) 1.24
Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J Neurosci (2013) 1.22
Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci (2010) 1.20
Layer-specific modulation of the prefrontal cortex by nicotinic acetylcholine receptors. Cereb Cortex (2012) 1.11
Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology (2010) 1.10
Nicotinic modulation of cortical circuits. Front Neural Circuits (2014) 1.09
Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci (2013) 1.08
Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav Neurosci (2011) 1.08
Deterministic functions of cortical acetylcholine. Eur J Neurosci (2014) 1.07
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol (2014) 1.04
CNTRICS final animal model task selection: control of attention. Neurosci Biobehav Rev (2012) 1.02
Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) (2011) 1.02
Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP). Behav Brain Res (2011) 1.01
The likelihood of cognitive enhancement. Pharmacol Biochem Behav (2011) 1.00
Mechanisms generating dual-component nicotinic EPSCs in cortical interneurons. J Neurosci (2012) 0.99
Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology (2010) 0.97
Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res (2012) 0.97
Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology (2011) 0.97
Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology (2012) 0.96
Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol (2014) 0.91
Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors. Br J Pharmacol (2013) 0.91
Neuromodulation by acetylcholine: examples from schizophrenia and depression. Curr Opin Neurobiol (2014) 0.90
Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. Psychopharmacology (Berl) (2011) 0.90
The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy. Front Physiol (2015) 0.88
Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. Eur J Neurosci (2012) 0.87
Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology (2012) 0.86
Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. Neuropsychopharmacology (2011) 0.86
Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behav Brain Res (2012) 0.86
Simulation of cholinergic and noradrenergic modulation of behavior in uncertain environments. Front Comput Neurosci (2012) 0.85
Time to pay attention: attentional performance time-stamped prefrontal cholinergic activation, diurnality, and performance. J Neurosci (2012) 0.85
Nicotinic acetylcholine receptor ligands, a patent review (2006-2011). Expert Opin Ther Pat (2011) 0.84
Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochem Pharmacol (2015) 0.84
nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophr Res (2016) 0.84
A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) (2013) 0.83
Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav (2011) 0.83
Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. Psychopharmacology (Berl) (2012) 0.83
Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex. Cell Mol Life Sci (2014) 0.82
Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals. Front Syst Neurosci (2014) 0.82
Task demands dissociate the effects of muscarinic M1 receptor blockade and protein kinase C inhibition on attentional performance in rats. J Psychopharmacol (2011) 0.81
Prefrontal neuromodulation by nicotinic receptors for cognitive processes. Psychopharmacology (Berl) (2012) 0.80
GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology (2015) 0.80
The effects of nicotine and non-nicotine smoking factors on working memory and associated brain function. Addict Biol (2015) 0.80
Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats. Biochem Pharmacol (2013) 0.79
Neuronal effects of nicotine during auditory selective attention. Psychopharmacology (Berl) (2014) 0.78
Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits. Neuropharmacology (2013) 0.78
Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology (Berl) (2014) 0.78
Cholinergic genetics of visual attention: Human and mouse choline transporter capacity variants influence distractibility. J Physiol Paris (2016) 0.78
Nicotine reduces distraction under low perceptual load. Psychopharmacology (Berl) (2014) 0.78
Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish. Psychopharmacology (Berl) (2013) 0.77
Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance. Neurobiol Learn Mem (2016) 0.77
Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology. ISRN Biochem (2012) 0.76
Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention. Psychopharmacology (Berl) (2016) 0.75
Developmental Ethanol Exposure Leads to Long-Term Deficits in Attention and Its Underlying Prefrontal Circuitry. eNeuro (2016) 0.75
Method for Testing Sustained Attention in Touchscreen Operant Chambers in Rats. J Neurosci Methods (2016) 0.75
Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's disease patients with defined cholinergic losses. Neuroimage (2017) 0.75
MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs. Psychopharmacology (Berl) (2017) 0.75
Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron (2007) 3.79
Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Brain Res Rev (2005) 3.24
Top-down control-signal dynamics in anterior cingulate and prefrontal cortex neurons following task switching. Neuron (2007) 2.61
More attention must be paid: the neurobiology of attentional effort. Brain Res Rev (2006) 2.51
Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol (2004) 2.22
Effect sizes and p values: what should be reported and what should be replicated? Psychophysiology (1996) 2.07
The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry (1989) 1.94
Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci (1996) 1.80
Transdermal nicotine effects on attention. Psychopharmacology (Berl) (1998) 1.61
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol (2007) 1.46
Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res (2000) 1.39
Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb Cortex (2005) 1.34
Rats and humans paying attention: cross-species task development for translational research. Neuropsychology (2008) 1.32
Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull (2005) 1.28
Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology (Berl) (2002) 1.27
The neural mechanisms for minimizing cross-modal distraction. J Neurosci (2004) 1.27
Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci (2008) 1.25
ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry (2006) 1.24
Attentional effects of nicotinic agonists in rats. Neuropharmacology (2003) 1.24
CNTRICS final task selection: control of attention. Schizophr Bull (2009) 1.21
Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci (2010) 1.20
A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry (1999) 1.20
nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol (2009) 1.13
Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl) (1999) 1.12
Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology (Berl) (2000) 1.09
Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology (Berl) (1998) 1.08
Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology (2007) 1.07
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) (1999) 1.04
Nicotine in an animal model of attention. Eur J Pharmacol (2000) 1.02
Selective effects of nicotine on attentional processes. Psychopharmacology (Berl) (1999) 0.99
A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology (Berl) (2008) 0.99
Moving out of the laboratory: does nicotine improve everyday attention? Behav Pharmacol (2000) 0.97
Preclinical research into cognition enhancers. Trends Pharmacol Sci (2006) 0.96
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol (2007) 0.95
Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) (1998) 0.95
Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacology (Berl) (1997) 0.95
Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology (Berl) (1995) 0.95
Nicotine-induced enhancements in the five-choice serial reaction time task in rats are strain-dependent. Psychopharmacology (Berl) (2001) 0.95
Selective inhibition of acetylcholine-evoked responses of alpha7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists. Mol Pharmacol (2009) 0.94
Attentional effects of nicotine and amphetamine in rats at different levels of motivation. Psychopharmacology (Berl) (2003) 0.93
Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology (2003) 0.92
Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci (2006) 0.82
Cognitive performance after mild traumatic brain injury: the impact of poor effort on test results and its relation to distress, personality and litigation. Brain Inj (2007) 0.79
Modulatory effects of S 38232, a non alpha-7 containing nicotine acetylcholine receptor agonist on network activity in the mouse hippocampus. Neuropharmacology (2009) 0.78
Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron (2007) 3.79
Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology (2010) 2.74
Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development. Genome Biol (2011) 2.18
Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci (2009) 1.94
High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene (2004) 1.78
Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci (2005) 1.77
Ventral hippocampal muscimol disrupts context-specific fear memory retrieval after extinction in rats. Hippocampus (2006) 1.73
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2012) 1.66
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation (2011) 1.56
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry (2006) 1.53
Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity. Ann N Y Acad Sci (2008) 1.52
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol (2012) 1.48
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov (2010) 1.47
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis (2012) 1.40
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in patients having combined coronary artery bypass grafting and valve surgery. Am J Cardiol (2011) 1.38
Persistent alterations in cognitive function and prefrontal dopamine D2 receptors following extended, but not limited, access to self-administered cocaine. Neuropsychopharmacology (2008) 1.36
Progress in the prediction of pKa values in proteins. Proteins (2011) 1.36
Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb Cortex (2005) 1.34
Rats and humans paying attention: cross-species task development for translational research. Neuropsychology (2008) 1.32
Rapid assessment of in vivo cholinergic transmission by amperometric detection of changes in extracellular choline levels. Eur J Neurosci (2004) 1.30
Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog Neurobiol (2007) 1.28
Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci (2008) 1.25
Microarray and comparative genomics-based identification of genes and gene regulatory regions of the mouse immune system. BMC Genomics (2004) 1.25
Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci (2011) 1.24
Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J Neurosci (2013) 1.22
CNTRICS final task selection: control of attention. Schizophr Bull (2009) 1.21
Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci (2010) 1.20
Challenges to attention: a continuous arterial spin labeling (ASL) study of the effects of distraction on sustained attention. Neuroimage (2010) 1.20
nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol (2009) 1.13
Effects of steric constraint on chromium(III) complexes of tetraazamacrocycles. Chemistry and excited-state behavior of 1,4-C2-cyclam complexes. Inorg Chem (2003) 1.11
Ascending visceral regulation of cortical affective information processing. Eur J Neurosci (2003) 1.10
A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome. Am J Obstet Gynecol (2009) 1.09
Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci (2013) 1.08
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res (2006) 1.08
Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology (2007) 1.07
Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract (2010) 1.04
Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther (2011) 1.03
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) (2011) 1.02
Differential expression of tomato spotted wilt virus-derived viral small RNAs in infected commercial and experimental host plants. PLoS One (2013) 1.02
Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. J Neurosci (2005) 1.02
Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP). Behav Brain Res (2011) 1.01
Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. J Pharmacol Exp Ther (2006) 1.01
Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology (2002) 1.01
Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology (2002) 1.01
Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol (2009) 1.01
The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention. J Neurosci (2013) 1.00
Cholinergic optimization of cue-evoked parietal activity during challenged attentional performance. Eur J Neurosci (2009) 1.00
Older people's use of NHS Direct. Age Ageing (2011) 1.00
Interactions between cognition and circadian rhythms: attentional demands modify circadian entrainment. Behav Neurosci (2009) 1.00
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol (2013) 0.99
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology (2009) 0.98
NMDA and dopamine interactions in the nucleus accumbens modulate cortical acetylcholine release. Eur J Neurosci (2005) 0.98
Randomised controlled feasibility trial of a web-based weight management intervention with nurse support for obese patients in primary care. Int J Behav Nutr Phys Act (2014) 0.97
Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: evidence from a translational Sustained Attention Task. Schizophr Res (2013) 0.96
CNTRICS final biomarker selection: Control of attention. Schizophr Bull (2011) 0.96
Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology (2012) 0.96
Does brief telephone support improve engagement with a web-based weight management intervention? Randomized controlled trial. J Med Internet Res (2014) 0.94
Applying molecular dynamics simulations to identify rarely sampled ligand-bound conformational states of undecaprenyl pyrophosphate synthase, an antibacterial target. Chem Biol Drug Des (2011) 0.94
Giardia lamblia aurora kinase: a regulator of mitosis in a binucleate parasite. Int J Parasitol (2007) 0.94
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther (2007) 0.94
Glutamate receptors in nucleus accumbens mediate regionally selective increases in cortical acetylcholine release. Synapse (2007) 0.94
Fli-1 transcription factor affects glomerulonephritis development by regulating expression of monocyte chemoattractant protein-1 in endothelial cells in the kidney. Clin Immunol (2012) 0.94
Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacology (Berl) (2002) 0.93
Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation. Neuropsychopharmacology (2006) 0.92
Maternal high-fat diet modulates the fetal thyroid axis and thyroid gene expression in a nonhuman primate model. Mol Endocrinol (2012) 0.92
The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician's point of view. Eur Child Adolesc Psychiatry (2011) 0.92
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci (2004) 0.91
Increases in cholinergic neurotransmission measured by using choline-sensitive microelectrodes: enhanced detection by hydrolysis of acetylcholine on recording sites? Neurochem Int (2008) 0.91
Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. Psychopharmacology (Berl) (2002) 0.91
CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). J Physiol (2014) 0.90
Bidirectional interactions between circadian entrainment and cognitive performance. Learn Mem (2012) 0.90
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.89
Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist. Neuropsychopharmacology (2012) 0.89
Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. Neuropsychopharmacology (2007) 0.89
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol (2006) 0.89
PlantID - DNA-based identification of multiple medicinal plants in complex mixtures. Chin Med (2012) 0.89
High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res (2003) 0.89
D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. Neuropharmacology (2007) 0.89
Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav Brain Res (2010) 0.87
Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment. Neuropsychopharmacology (2009) 0.87
Lateralized attentional functions of cortical cholinergic inputs. Behav Neurosci (2004) 0.87
Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. Eur J Neurosci (2012) 0.87
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol (2005) 0.87
Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behav Brain Res (2012) 0.86
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav (2011) 0.86
Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol (2008) 0.86
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol (2006) 0.86
Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci (2013) 0.86
Interactions between aging and cortical cholinergic deafferentation on attention. Neurobiol Aging (2002) 0.85
Eating disorders patients' views on their disorders and on an outpatient service: a qualitative study. J Health Psychol (2008) 0.85
Causes of death among patients with chronic fatigue syndrome. Health Care Women Int (2006) 0.85
Time to pay attention: attentional performance time-stamped prefrontal cholinergic activation, diurnality, and performance. J Neurosci (2012) 0.85
Microdialysis without acetylcholinesterase inhibition reveals an age-related attenuation in stimulated cortical acetylcholine release. Neurobiol Aging (2003) 0.85
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology (Berl) (2011) 0.85
Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats. Biol Psychiatry (2005) 0.84